What factors drove the changes in biote's revenue and profit?

What were the key takeaways from biote’s earnings call?

What is the market's earnings forecast for biote next quarter?

What does biote do and what are its main business segments?

What is biote's latest dividend and current dividend yield?

What were the key takeaways from biote's earnings call?

What is the revenue and EPS growth rate for biote year over year?

Did biote beat or miss consensus estimates last quarter?

- **Strategic Rebuild Progress**: 75%-80% of planned sales rep headcount achieved, with 85% of targeted hires on track for year-end.
- **Financial Performance**: Q3 revenue down 6.7% ($48.0M), with dietary supplements up 8.4%, gross margin +150bps to 71.8%.
- **Attrition Management**: Elevated attrition rate at 8%, with focus on improving provider retention and new business growth.
- **Cash Flow Optimization**: $20.6M in settlements with Donovitzes, reducing future obligations by $18.6M.
- **Operational Efficiency**: 50% of procedures fulfilled through Asteria, with plans to convert remaining clinics in 2026.
- **Nutra Growth**: E-commerce channel drives mid-teens revenue growth, supported by new product launches.
- **Long-Term Outlook**: 2025 guidance for >$190M revenue and >$50M adjusted EBITDA.

**【CEO Summary Section】**
- CEO Bret Christensen outlined three strategic priorities: accelerating growth from new providers, maximizing value from top-tier clinics, and improving financial performance through accountability and discipline.
- Management emphasized rebuilding the commercial team, with approximately half of the commercial team hired in the past year. The company is 75%-80% of the way to achieving planned sales rep headcount, with a focus on training and onboarding new reps.
- The annual marketing event in September attracted over 800 attendees, reinforcing Biote's leadership in hormone optimization and evidence-based care.

**【CFO Financial Commentary】**
- Q3 2025 revenue decreased 6.7% to $48.0 million, with procedure revenue down 10.4% and dietary supplements up 8.4%.
- Gross profit margin improved by 150 basis points to 71.8%, driven by cost savings and operational efficiency.
- Selling, general, and administrative expenses increased 9.3% to $26.2 million, reflecting investments in sales and marketing.
- Adjusted EBITDA decreased 20.5% to $12.9 million, with a margin of 26.9%.
- The company repurchased 1 million shares under a $20 million buyback program and settled multiyear obligations with Marci and Gary Donovitz for $12.5 million and $18.5 million, respectively.

**【Q&A Highlights】**
- Sales force ramp-up: New hires require 3-6 months to reach full productivity, with 85% of targeted headcount achieved by year-end.
- Attrition trends: Q3 attrition rate remained elevated at 8%, driven by competition and slower new business growth.
- Asteria adoption: 50% of procedures fulfilled through Asteria, with plans to convert remaining clinics in 2026.
- Nutra business growth: Mid-teens revenue growth expected, supported by e-commerce channel expansion.
- Donovitz transactions: Cash flow savings of $7.5 million (Marci) and $11.1 million (Gary), with non-compete agreements extended to 2027.

**【Strategic Initiatives】**
- Biote's annual marketing event reinforced provider relationships and education, with 800+ attendees and expert speakers.
- Focus on improving commercial team effectiveness, including training and onboarding new reps to drive procedure volume recovery.
- Long-term financial outlook: 2025 revenue guidance above $190 million and adjusted EBITDA above $50 million.


biote Corp. (BTMD) Q3 2025 Earnings Call Transcript

- **Strategic Reorganization**: CEO Bret Christensen outlined a restructured organization to drive growth, with new leadership and sales incentives, despite Q2 procedure revenue decline of 8.4%.
- **Financial Performance**: CFO Bob Peterson reported flat Q2 revenue ($48.9M) due to procedure shortfall, offset by 30% dietary supplement growth. Adjusted EBITDA rose 19.1% to $15.2M, with revised 2025 guidance for >$190M revenue and >$50M EBITDA.
- **Key Challenges**: Higher clinic attrition, lower procedure volumes, and CDSS software disruption impacted results. Vertical integration of manufacturing improved gross margin to 71.6%.
- **Q&A Insights**: Management expects procedure recovery in 2026, with focus on sales force restructuring and value proposition improvements. Dietary supplements remain a growth driver.

**【Management Opening Remarks】**
- Szymon Serowiecki provided an overview of the Q2 2025 financial results and reminded participants of the risks associated with forward-looking statements. He highlighted the use of non-GAAP measures like adjusted EBITDA and provided a reconciliation to GAAP metrics.

**【CEO Summary Section】**
- **Strategic Reorganization**: Implemented in May 2025, focused on people, processes, and culture to drive sustainable growth. Key objectives include accelerating new provider wins, strengthening existing relationships, and improving financial performance.
- **Commercial Initiatives**: Hired new leadership (e.g., Joey Lopes as Senior VP of Strategy), revamped sales compensation to incentivize new clinic additions and revenue growth, and enhanced sales training programs.
- **Challenges**: Procedure revenue declined due to slower new clinic additions, higher-than-normal attrition, and lower procedure volumes. These issues were exacerbated by the CDSS software disruption and organizational changes.
- **Long-term Vision**: Committed to improving the value proposition for providers to enhance retention and attract new customers, despite short-term disruptions.

**【CFO Financial Commentary】**
- **Revenue**: Q2 2025 revenue was $48.9 million, flat year-over-year. Procedure revenue declined 8.4%, offset by 30.4% growth in dietary supplements ($10.7 million).
- **Gross Margin**: Improved to 71.6% (up 280 bps) due to cost savings from vertical integration of the 503B manufacturing facility.
- **Expenses**: SG&A decreased 12.2% to $24.2 million, driven by headcount adjustments and timing of marketing events.
- **Profitability**: Net income was $3.9 million (vs. $10.4 million loss in Q2 2024), with adjusted EBITDA up 19.1% to $15.2 million (31.1% margin).
- **Cash Flow**: Operating cash flow was $7.1 million for Q2 and $13.6 million for H1, with cash reserves at $19.6 million.
- **Guidance Update**: Revised 2025 revenue guidance to >$190 million (from prior range) and adjusted EBITDA to >$50 million, reflecting procedure revenue declines and dietary supplement growth.

**【Q&A Key Highlights】**
- **Verticalization Progress**: 40-50% of pellets now manufactured internally, with plans to resume penetration efforts in Q3 to improve margins.
- **Procedure Decline Causes**: Attributed to CDSS launch disruption (Q3 2024), reorganization, and macroeconomic factors. Attrition and volume declines in existing clinics also impacted results.
- **Sales Force Restructuring**: Smaller territories, growth-focused compensation, and consolidated leadership to drive new clinic additions. New hires and training programs aim to reinvigorate the team.
- **Market Dynamics**: Denied GLP-1 competition as a factor, emphasizing HRT and GLP-1 complementarity. Focused on internal initiatives to improve retention and growth.


biote Corp. (BTMD) Q2 2025 Earnings Call Transcript

- **Topline Growth**: Q1 revenue up 4.7% to $49M, driven by 25.5% dietary supplement surge
- **Margin Expansion**: Gross margin +300bps to 74.3% from manufacturing vertical integration
- **Strategic Restructuring**: +25% field sales team expansion to accelerate new clinic growth
- **Challenges**: Procedure revenue down 3.6% due to CDSS rollout disruption
- **2025 Outlook**: $202M-$208M revenue guidance, 2%–4% procedure growth target
- **Key Risk**: Ongoing price competition in procedure business

**【CEO Summary Section】**
- Q1 2025 revenue increased 4.7% to $49.0 million, driven by a 25.5% surge in dietary supplement revenue ($9.3 million) offsetting a 3.6% decline in procedure revenue ($36.0 million). 
- Gross profit margin improved 300 basis points to 74.3% due to vertical integration of the 503(b) manufacturing facility.
- Announced strategic restructuring to accelerate new clinic growth: 
  - Expanded field sales team by 25% (20+ new roles)
  - Streamlined sales leadership and updated comp plans
  - Focus on supporting new providers with dedicated field resources
- 2025 priorities: 
  1. Accelerate new provider wins
  2. Strengthen top-tier clinic relationships
  3. Improve commercial accountability

**【CFO Financial Commentary】**
- GAAP net income: $15.8M (vs. $5.7M loss in Q1 2024), driven by $10.7M gain from earn-out liability revaluation
- Adjusted EBITDA: $13.8M (-3.4% YoY) with margin of 28.1%
- Key metrics: 
  - SG&A expenses +16.4% to $26.7M (due to sales & marketing investments)
  - Cash flow from operations: $6.5M
  - Ending cash: $41.7M
- 2025 guidance: 
  - Revenue: $202M-$208M
  - Adjusted EBITDA: $59M-$64M
  - Q2 2025 outlook: Similar to slightly higher than Q2 2024
  - One-time restructuring charge: $0.6M-$0.8M

**【Q&A Key Themes】**
1. **Dietary Supplements Growth**: 
  - E-commerce channel led 25.5% increase
  - No one-time items; solid runway for continued expansion
2. **Procedure Revenue Challenges**: 
  - Headwinds from CDSS rollout (fully deployed now)
  - New clinic additions slowed in Q1
  - Base business volume decline (+5% attrition rate stable)
3. **Competitive Landscape**: 
  - Price-based competition persists
  - Differentiate via education, training, and clinical support
4. **Restructuring Impact**: 
  - Field sales expansion expected to accelerate new starts
  - Early indicators (training volumes) to track progress
  - Full results likely in H2 2025

biote (BTMD)-7 May 25-2025 Q1 Earnings call transcript

- **2025 Growth Target**: 2-4% procedure revenue growth via 50% new practitioners, 50% existing base expansion.
- **Margin Strength**: 71.8% gross margin driven by Asteria vertical integration.
- **Digital Platform**: Enhanced CDSS adoption leading to 15%+ patient satisfaction improvements.
- **Cash Position**: $39.3M as of Q4, with $45.2M annual cash flow.
- **New Customer Focus**: $15M+ annual investment in sales/marketing to reaccelerate quickstart program.

**【Executive Chairman Opening Remarks】**
- Biote has strengthened its competitive position through strategic acquisitions (Asteria Health) and product enhancements (BioteRx platform, upgraded clinical decision support software). 
- Vertical integration of 503B manufacturing has improved gross margin by 247bps YoY to 71.8%.
- New CEO Bret Christensen emphasizes focus on practitioner training, software adoption, and new customer growth.

**【CFO Financial Review】**
- Q4 2024 revenue: $49.8M (+9% YoY), driven by procedure (+5%) and supplement (+10.2%) growth.
- Adjusted EBITDA: $15.1M (+11.4%), margin 30.3%.
- FY2024 cash flow: $45.2M, ending with $39.3M cash.
- 2025 Outlook: Revenue $202-208M, EBITDA $59-64M; Q1 2025 EBITDA ~5% lower due to sales/marketing investments.

**【CEO Strategic Priorities】**
1. Maximize value from top-tier providers via enhanced CDSS and training.
2. Accelerate new practitioner onboarding (quickstart program) to drive 2-4% procedure growth.
3. Improve commercial execution discipline for consistent revenue generation.

**【Q&A Highlights】**
- Procedure growth 2-4% in 2025: 50%+ from new practitioners, 50% from existing base.
- GLP-1s represent <10% of revenue, not core focus.
- No material patient churn from CDSS transition; practitioners report improved patient outcomes.
- Amazon channel driving supplement growth, expects 5-10% YoY expansion.
- Asteria manufacturing capacity fully utilized; internal pellet production >70% of needs.
- 2025 SG&A spend to increase ~15% to support new customer acquisition.

biote (BTMD)-12 Mar 25-2024 Q4 Earnings call transcript

biote (BTMD)-12 Nov 24-2024 Q3 Earnings call transcript

biote (BTMD)-8 Aug 24-2024 Q2 Earnings call transcript

biote Corp - Ordinary Shares (BTMD)-7 May 24-2024 Q1 Earnings call transcript

biote Corp - Ordinary Shares (BTMD)-12 Mar 24-2023 Q4 Earnings call transcript

- **Revenue Growth**: Q3 revenue up 8.5% YoY to $45.6 million, with adjusted EBITDA rising 14% to $14 million.
- **Procedure Challenges**: Slowed growth due to volume discounts and GLP-1 competition, but new clinics show early promise.
- **Wellness Expansion**: Launching a comprehensive wellness platform in Q1 2024 after successful trials, targeting expanded TAM.
- **Financial Outlook**: 2023 guidance at lower end of $190-200 million revenue, with Q4 benefit from new supplements and promotions.
- **Men's Health Focus**: Strengthening partnerships and educational programs to capture growing male health market share.


**【CEO Summary Section】**
- Q3 2023 revenue grew 8.5% YoY to $45.6 million, driven by 7.4% procedure revenue growth and 5.1% dietary supplements growth.
- Adjusted EBITDA increased 14% YoY to $14 million, with a margin of 30.8%.
- Procedure revenue growth slowed due to volume discounts to top practitioners and competition from GLP-1 weight loss products.
- Launching a new therapeutic wellness platform in Q1 2024 after successful trials with 30 providers, showing strong patient and provider feedback.
- Men's health initiatives include partnerships with key opinion leaders and educational programs to expand market share.

**【CFO Financial Commentary】**
- Gross profit margin improved to 68.9% due to cost management.
- Selling, general, and administrative expenses rose 14.3% YoY to $23.8 million, driven by share-based compensation and legal expenses.
- Net income reached $19.6 million, up from $0.5 million YoY, primarily due to fair value changes in earn-out liabilities.
- 2023 guidance: Revenue $190-200 million, adjusted EBITDA $56-60 million, with expectations to meet the lower end of the range.
- Q4 outlook includes new supplement launches and seasonal promotions.

**【Q&A Highlights】**
- **Wellness Platform Competition**: Biote's expanded suite of hormone and wellness solutions aims to become the single-source provider, with nationwide launch in Q1 2024.
- **Procedure Growth Challenges**: Volume discounts and GLP-1 competition offset by new clinic onboarding, with 12-month procedure growth improving for new providers.
- **Sales Force Transition**: Accelerated practitioner onboarding and clinic growth, despite delayed revenue impact.
- **Manufacturer Relationships**: Strong partnerships ensuring access to new wellness products for commercial trials.


BTMD

BTMD fundamentals

Earnings Call

You can ask Aime